This report further characterizes the intermediate metabolic effects of the psychotropic amphetamine derivative, 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy")
for releasing 5-HT, inhibiting its reuptake, and producing the degeneration of presynaptic serotonergic elements (Johnson et al. 1986; Schmidt 1987; Commins et al. 1987; Battaglia et al. 1988; O'Hearn et al. 1988; Ricaurte et al. 1988; Insel et al. 1989; Fischer et al. 1995) . However, the intermediate metabolic changes that occur and ultimately result in 5-HT fiber loss have not been investigated thoroughly (for a review, see Steele et al. 1994) .
Among its many pharmacological characteristics, MDMA has been reported to influence intracellular calcium dynamics. Acutely, MDMA induces a concentration-dependent increase in calcium uptake into cortical synaptosomes (Park and Azmitia 1991; Azmitia et al. 1993) . Furthermore, long-term reductions in 5-HT biomarkers, as well as changes in astrocyte responses, are attenuated by MK-801 and nimodipine-antagonists for the NMDA-sensitive Ca 2 ϩ channel and the L-type Ca 2 ϩ channel, respectively-supporting the existence of a calcium-dependent component in MDMA's long-term effects (Azmitia 1989; Azmitia et al. 1990; Farfel et al. 1992; Pu and Vorhees 1995) . These observations suggest that calcium-dependent second messenger systems could be involved in the development of MDMA-mediated serotonergic neurodegeneration. One such pathway may involve the calcium-activated and phospholipid-dependent enzyme, protein kinase C (PKC) (Berridge 1984; Nishizuka 1986) . PKC is abundant in 5-HT neurons, surrounding glial cells, and is activated in both cell types through stimulation of the 5-HT 2A/2C receptor Sanders-Bush 1985, 1986; Wang and Friedman 1990; Kagaya et al. 1990; Masliah et al. 1991; Gott et al. 1994) .
Numerous experiments have shown that several of MDMAs'acute (hyperthermia and dopamine release) and neurotoxic effects arise through interactions with the central 5-HT 2A/2C receptor (Schmidt et al. 1991; Malberg et al. 1994; Poblete and Azmitia 1995) . These findings are consistent with MDMA's agonist-like properties at the 5-HT 2A/2C receptor, which include the potentiation of DA release and the acceleration of glycogenolysis in astrocytes (Nash 1990; Poblete and Azmitia 1995) . Pretreatment of primary cultured serotonergic neurons with the 5-HT 2A antagonist, ketanserin, reduces their susceptibility to toxic concentrations of MDMA (Azmitia et al. 1990 ). In vivo, Schmidt et al. (1990) have shown that hyperthermia and long-term reductions in cortical, hippocampal, and striatal 5-HT content are competitively reversed by pretreatment with the 5-HT 2A/2C antagonist, MDL 11,939.
In vitro, activation of the 5-HT 2A/2C receptor begins the G-protein-linked hydrolysis of phosphotidylinositol 4,5-bisphosphate (PIP 2 ), which liberates diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP 3 ) Sanders-Bush 1985, 1986; Kendall and Nahorski 1985; Nishizuka 1986 ). Inositol trisphosphate stimulates the release of calcium from intracellular stores, which ultimately increases [Ca 2 ϩ ] i concentration (Kendall and Nahorski 1985) . Both of these metabolic intermediates contribute to the translocation of PKC to the plasma membrane (Berridge 1984; Nishizuka 1986; Manev et al. 1990 ). Under basal conditions, PKC exists inactively as a soluble cytosolic enzyme but becomes translocated to the plasma membrane (in its active form) upon receptor stimulation by hormones, neurotransmitters, or directly by tumor-promoting phorbol esters (Castanga et al. 1982; Wolf et al. 1985) . The translocation of PKC is believed to be the primary process by which it becomes biologically active (Favaron et al. 1988) .
It is known that MDMA's parent compound, amphetamine, which promotes the release of dopamine (DA) from rat brain synaptosomes, has been shown to increase PKC translocation and activity in vivo and within synaptosomes (Giambalvo 1992a,b) . We have previously reported that multiple injections of MDMA produce a long-term translocation of PKC to rat cortical membranes; however the localization (either pre or postsynaptic) of the MDMA-sensitive PKC pool remained undefined (Kramer and Azmitia 1994; Kramer et al. 1995) . Since the prolonged translocation of PKC has been implicated in several calcium-dependent neurodengenerative processes including ischemia (Manev et al. 1990 ), its possible role in MDMA-induced neurotoxicity is currently under investigation. MDMA, which itself produces a 5-HT 2A/2C receptor and Ca 2 ϩ -dependent form of neurotoxicity, may require the activation of PKC. In this report, we extend the findings of our previous study to conclude that MDMA produces PKC translocation through two separate mechanisms: (1) the stimulation of 5-HT 2A/2C receptors and (2) through an interaction with the 5-HT uptake carrier (SERT).
METHODS

Animal Care and Handling
Female Sprague-Dawley rats (weighing between 150-200 g; Taconic Farms, Germantown, NY) were used for all experiments. All animals were maintained on a 12-h light/dark cycle and had free access to food and water. All animal protocols were reviewed and approved by the New York University animal welfare committee.
(NIDA); Bethesda, MD), or p-chloroamphetamine (pCA; Sigma, St. Louis, MO). The treatment regimens were comprised of one or two injections per day. Thirty minutes to 7 days after the last injection, the animals were decapitated and their brains rapidly removed followed by careful dissection of the cerebral cortex, hippocampus, and brainstem. Fresh or frozen tissue samples were thawed and homogenized in an ice-cold buffer that limited active proteolysis. This buffer contained (mmol/L): Tris-HCl 20; ethylenediaminetetraammonium (EDTA) 2.0; phenylmethylsulfonyl fluoride (PMSF) 0.2; and ethyleneglycoltetraacetate (EGTA) 0.5 at pH 7.4. Tissue was homogenized in 10 ϫ v/w weight using a glass/teflon homogenizer or a Tissue Tearer Polytron (Brinkman). Samples were centrifuged in a Sorvall RC-5C centrifuge (using an SS-34 fixed-angle rotor) at 2,400 g for 10 min to remove blood and other microsomal fractions. After discarding the pellet (P1), the supernatant was centrifuged for 15 min at 48,000 g to separate plasma membranes from the cytosolic fraction. The resulting pellet was resuspended in 40 ϫ original v/w weight in resuspension buffer containing (mmol/L): Tris-HCl (38.5); Tris-Base (11.5); NaCl (100); and CaCl 2 (1.0) at pH 7.4.
For radioligand binding, 40 l (0.1 mg of protein as assessed by the method of Lowry et al. 1951 ) of membranes were plated onto 96-well plates (Nunc, Denmark) and allowed to equilibrate with 20 l of either assay buffer or 3 mol/L phorbol 12-myristate 13-acetate (PMA; Sigma) to determine nonspecific binding. Scatchard analyses were performed to determine total binding and the initial 3 H-PDBu binding parameters (K D and B max ) using 3 H-PDBu (1-40 nmol/L) (New England Nuclear, specific activity 18.6 Ci/mmol) in a total well volume of 200 l for 45 min at room temperature. Onepoint determinations were used to assay the number of translocated PKC binding sites (7 nmol/L 3 H-PDBu) in some experiments. The tissue was harvested onto Titertek filtermats (coated with 0.1% polyethylimine (PEI) to reduce nonspecific binding) using a Titertek cell harvester, and the filters were placed in scintillation vials containing 3.0 ml of Liquiscint (National Diagnostics). Samples were counted for 5 min in a Beckman liquid scintillation counter at an efficiency 40%.
Specific
H-paroxetine Binding to Cortical Membranes
Tissue was thawed to 4 Њ C and homogenized at 40 ϫ v/ w in Tris-HCl buffer containing (mmol/L): Tris-HCl (38.5); Tris-Base (11.5); NaCl (120); and KCl (5.6) at pH 7.4 using a Brinkman polytron. The tissue was centrifuged at 30,000 g for 25 min, and the resultant pellet was resuspended in 80 ϫ v/w in normal Tris HCl. Then 160 l of membrane homogenate (0.090-0.120 mg of protein) was incubated in the presence of either 40 l of Tris-HCl buffer (total binding) or 1 mol/L fluoxetine (Lilly, Indianapolis, IN; nonspecific binding) for 5 min, and 200 l of 3 H-paroxetine (final concentration 0.25 nmol/L; specific activity 15.3 Ci/mmol New England Nuclear) was added and allowed to equilibrate in the dark for 120 min at 22 Њ C. Membrane filtration and radioactivity measurement proceeded as indicated above. H-paroxetine binding curves were analyzed using an iterative curve fitting program. One-way and two-way analyses of variance (ANOVA) and the post hoc Tukey test were used for multiple comparisons at a minimum significance level of p Յ .05. Student's t -test was used when applicable for simple twosample tests. All statistical data was expressed as mean Ϯ SD of the indicated number of observations. Rats were injected with either saline or a single dose of MDMA in the range of 2.5-40 mg/kg. One-point determinations (7 nM; 3 H-PDBu) were used to assay the redistribution of PKC binding sites to the plasma membrane of cortical and hippocampal samples. At 3 h postinjection, MDMA produced a concentration-dependent increase in membrane-bound (particulate) PKC in the cortex beginning with the 10 mg/kg dose and continuing through the 40 mg/kg treatment ( Figure 2 ). MDMA at 10 and 20 mg/kg increased the number of and 52.8% (17.1 pmol/mg protein) over saline controls (11.18 Ϯ 0.91 pmol/mg protein; p Յ .001), respectively. Nonlinear curve-fitting analysis showed that MDMA produced a half-maximal translocation of 3 H-PDBu binding sites at 22.5 mg/kg. This stimulatory effect plateaus at doses Ն 30 mg/kg (90.3% increase over control). In the hippocampus, MDMA elicited similar results by increasing membrane PKC density only with doses greater than 10 mg/kg (data not shown). In contrast to the changes in 3 H-PDBu binding density, no alterations in ligand binding affinity occurred in the hippocampus or cortex after any dose of MDMA. During these dose-response experiments, two of the eight animals that received the highest dose (40 mg/kg) of MDMA died from the treatment.
Data Analysis and Statistics
RESULTS
Initial
We then investigated the time-course (30 min-24 h) of MDMA-induced PKC activation after a single drug exposure (20 mg/kg). MDMA significantly increased the number of cortical PKC sites beginning at 3 h after injection, and this translocation remained significantly above control for 24 h (Figure 3 ). MDMA increased the number of plasma membrane PKC sites by: 67.9% (3 h), 60.9% (6 h), 66.6% (12 h), and 60.4% (24 h) ( Figure 3 ). Scatchard analysis showed there was no difference in ligand binding affinity in any of the observed groups where a significant translocation was reported (data not shown). By 48 h after injection, the amount of particulate PKC was not significantly different than that observed in saline treated animals, nor were there any changes in ligand affinity. 
Comparison of MDMA to Other Neuroactive Compounds for PKC Translocation
Rats received a single dose of either pCA (10 mg/kg), DOB (5 mg/kg), cocaine (COC-10 mg/kg), or fluoxetine (FLX-20 mg/kg) and were assayed for cortical PKC translocation at intervals ranging from 30 min to 24 h. PCA elicited a significant translocation of PKC beginning at 60 min after injection (saline ϭ 9.98 Ϯ 0.56 pmol/mg protein vs. 14.04 Ϯ 0.02 pmol/mg protein; (40.6%) p Յ .05) ( Table 1) . Maximal translocation occurred 6 h after treatment (64.0%: saline ϭ 10.45 Ϯ 0.42 pmol/mg protein vs. 17.14 Ϯ 0.20 pmol/mg protein; Figure 2 . Rats received either saline or (ϩ)-MDMA and were assayed for the redistribution of cortical 3 H-PDBu binding sites 3 h later.
3 H-PDBu binding to cortical membranes was performed as explained in the methods section. Asterisks indicate that the observed values were significantly different from the saline treated group at the p Յ .001 level using a one-way ANOVA (F (6,21) ϭ 132.23 with F crit ϭ 2.57). The data points represent specific binding of 3 H-PDBu to rat brain cortical membranes. Each data point is the average Ϯ SD of four determinations performed over three experiments (n ϭ 3). 3 H-PDBu binding to cortical membranes was performed as explained in the methods section. Asterisks indicate that the observed values were significantly different from the saline treated group at the p Յ .01 level using one-way ANOVA (F (7, 24) ϭ 136.78 with F crit ϭ 2.42). The data points represent specific binding of 3 H-PDBu to rat brain cortical membranes. Each data point is the average Ϯ SD of four determinations performed over three experiments (n ϭ 3). p Յ .05) and remained significantly above control for 12 h. The density of membrane-bound PKC binding sites returned to control levels by 24 h post-treatment. Neither cocaine, fluoxetine, nor DOB produced a significant increase in membrane-bound PKC binding sites across any of the time points investigated (Table 1) .
Effect of Fluoxetine (20 mg/kg) Pretreatment on MDMA-Mediated PKC Translocation
Rats were pretreated with fluoxetine (20 mg/kg) 1 h before receiving MDMA (20 mg/kg) or saline. Animals were killed 3 h after MDMA and assayed for 
Effect of Ketanserin (10 mg/kg) Pretreatment on MDMA-Mediated PKC Translocation
Rats were pretreated with KET (10 mg/kg) 1 h prior to receiving a single injection of pCA (10 mg/kg) or MDMA (20 mg/kg). Three h or 14 days later the animals were decapitated and their corticies assayed for PKC distribution and the number of 5-HT nerve terminals. Both MDMA and pCA increased the amount of membranebound 3 H-PDBu binding sites by 59.3 and 60.6%, respectively, 3 h after administration ( Figure 5 ). Ketanserin had no effect on PKC translocation by itself (saline: 10.35 Ϯ 1.03 versus KET: 8.57 Ϯ 0.66 pmol/mg protein). However, ketanserin pretreatment (60 min) significantly reduced (p Յ .05 by ANOVA) PKC translocation when given prior to each of the substituted amphetamines (Ϫ18.7% decrease from maximum for MDMA alone and Ϫ21.5% from pCA alone). Interestingly, membrane-bound PKC levels for both the KET/MDMA and KET/pCA groups remained significantly above control values despite the presence of the antagonist (KET/MDMA: 13.51 Ϯ 0.72 and KET/pCA: 13.05 Ϯ 0.75 pmol/mg protein; p Յ .05).
Finally, a subset of these animals were allowed to survive for 2 weeks before being assayed for cortical 5-HT innervation by 
DISCUSSION
Our previous report concluded that two injections of MDMA (20 mg/kg) were sufficient to increase the den- H-PDBu sites in rat cortical homogenates (Kramer et al. 1994 (Kramer et al. , 1995 . This increase within the particulate fraction was due to the translocation of cytosolic PKC to the plasma membrane. However, since MDMA has actions at both the 5-HT transporter and on postsynaptic 5-HT receptors, this study aimed to clarify which of these process(es) are involved in substituted amphetamine-induced PKC translocation.
The magnitude and duration of MDMA's long-term neurodegenerative effects are similarly dependent on Each bar is the average Ϯ SD of four animals and each experiment was repeated at least three times (n ϭ 3). The data bars represent specific binding of 3 HPDBu to rat brain cortical membranes. *p Յ .001 compared to saline-treated groups by ANOVA (F (5,18) ϭ 10.47) and the post hoc Tukey test. ⌬ Յ .05 when compared to the MDMA or pCA alone treated groups using similar statistical measures. the dose given to rats and non-human primates (Ricaurte et al. 1988) . MDMA administered at low concentrations (2.5-5.0 mg/kg) does not produce PKC translocation (Figure 2 ) nor does it produce neurotoxicity, suggesting that PKC translocation may be an intermediate step culminating in cell damage (Battaglia et al. 1987 Broening et al. 1994) . These lower doses, however, do release 5-HT in vitro and in vivo and suggest that neurotransmitter release, alone, is not enough to promote long-term 5-HT deficits. For instance, administration of the R-(Ϫ) form of MDMA produces an acute, but not a long-term depletion in brain (Schmidt 1987) . Lasting decreases in serotonergic biomarkers (5-HT, 5-HIAA, and 3 H-paroxetine binding sites) are only observed with doses of MDMA greater than 10 mg/kg (Commins et al. 1987; Battaglia et al. 1988; Broening et al. 1994) . Amphetamine (AMPH), which is a potent DA releaser, also produces PKC translocation and is correspondingly neurotoxic to DA-containing nerve terminals after high doses (Fisher and Cho 1979; Giambalvo 1992a,b) .
MDMA-mediated PKC translocation was also found to be dependent on time. A single injection of MDMA (20 mg/kg) produced a significant increase in particulate PKC density lasting from 3 h to 24 h after MDMA administration. This time course is similar to MDMA's 5-HT release profile, in vivo (Schmidt 1987 ). MDMA's ability to increase synaptic 5-HT arises from a direct interaction with the high-affinity 5-HT transporter, which is found on both neurons and glial cells (Kimelberg 1986; Berger et al. 1992a,b; Rudnick and Wall 1992a,b) . Single injections of MDMA (10-20 mg/kg) acutely deplete cortical and striatal 5-HT levels between 3 and 6 h after administration (Schmidt 1987; Schmidt and Taylor 1987; Broening et al. 1994) . These results support the hypothesis that increased extracellular 5-HT contributes to PKC activation in neural tissue Sanders-Bush 1985, 1986; Kagaya et al. 1990) . By 48 h after MDMA exposure, there was no measurable difference in cortical PKC binding sites between treatment groups. The loss of MDMA's kinase translocating effect may be due to the elimination of MDMA from the body, or the cessation of the 5-HT release response (Cho et al. 1990 ).
We then carried out similar experiments using a variety of 5-HT agonists. PCA (10 mg/kg) is a potent 5-HT releaser/uptake inhibitor and degenerates 5-HT nerve terminals similarly, but more potently than MDMA (Fuller et al. 1975) . DOB (5.0 mg/kg), a hallucinogen, is a selective 5-HT 2A/2C receptor agonist that has been found to translocate PKC in brain slices (Kagaya et al. 1990 ). Finally, two 5-HT uptake inhibitors were chosen, fluoxetine (FLX: 20 mg/kg) and cocaine (COC: 10 mg/kg), because of their ability to increase synaptic 5-HT levels by inhibiting the 5-HT uptake transporter. PCA (10 mg/kg) elicited a significant translocation of PKC in the cortex beginning at 1 h, and this response remained significantly above control through 12 h post-injection (Table 1). PCA produced its peak effects on PKC activation at 3 h (ϩ57.96% over saline), whereas MDMA induced a steady translocation, which did not change in intensity, during the period in which it was mobilized (3-24 h). Twelve hours after pCA administration, the density of membrane PKC sites was already beginning to decline from its peak level (Table 1 ). The density of 3 H-PDBu sites returned to control levels by 24 h after a single Figure 6 . Rats were pretreated with either saline or ketanserin (10 mg/kg) 1 h prior to receiving saline, pCA (10 mg/kg), or MDMA (20 mg/ kg). Two weeks after receiving the second injection, the animals were killed and their brains prepared for 3 H-paroxetine binding to cortical membrane homogenates.
3 H-paroxetine binding was performed as indicated in the methods section. Each bar is the average Ϯ SD of four animals and each experiment was repeated at least three times (n ϭ 3). The data bars represent specific binding of 3 H-PRX to rat brain cortical membranes. *p Յ .001 compared to saline-treated groups by ANOVA (F (5,18) ϭ 10.47) and the post hoc Tukey test. pCA exposure, whereas translocation produced by MDMA remained significantly above control at that time.
PCA is a potent 5-HT releaser, uptake inhibitor (EC 50 : 3.43 mol/L and IC 50 : 0.184 mol/L, respectively), and a powerful 5-HT neurotoxin, which causes selective ablation of fine 5-HT-IR axons after relatively low doses (0.5-2.5 mg/kg) (Harvey et al. 1975; Johnson et al. 1991; Berger et al. 1989 Berger et al. , 1992a . In comparison, higher concentrations of MDMA are required for inhibiting 5-HT uptake and promoting its release (IC 50 : 0.425 mol/L and EC 50 : 7.96 mol/L, respectively) compared to pCA (Johnson et al. 1991; Berger et al. 1992b ). Consequently, the time discrepancies observed for PKC translocation, and the development of neurotoxicity by MDMA and pCA, may reflect each compound's relative ability to increase synaptic 5-HT levels (Schmidt and Taylor 1987; Berger et al. 1992b; Kokotos Leonardi and Azmitia 1994) . PCA produces lasting changes in the 5-HT innervation of the forebrain (loss of 3 H-paroxetine binding sites) as early as 24 h after exposure, but similar changes after MDMA are not observed for at least 3 days Steele et al. 1994) . Consequently, the increased potency of pCA as a 5-HT releaser could explain why its temporal-response curve for PKC translocation lies to the left of MDMA's (Table 1 and Figure 3) .
Several other agents were tested for their potential for PKC activation, in vivo. Other 5-HT activating drugs like cocaine (10 mg/kg) (DA, NE, and 5-HT uptake inhibitor), DOB (5 mg/kg) (potent 5-HT 2A/2C agonist), and fluoxetine (20 mg/kg) (selective 5-HT uptake inhibitor) did not increase the density of membrane bound PKC sites, nor affect ligand affinity at any time point investigated (Table 1) . The lack of effect of acute FLX, COC, and DOB on PKC translocation may underlie their low neurodegenerative potential. Fluoxetine (10 mg/kg) administered for 21 days was found to actually upregulate the density of 3 H-paroxetine binding sites in the cortex and hippocampus (Hrdina and Vu 1993) . These changes are dissimilar to those reported after MDMA and pCA exposure and suggest that uptake inhibition alone does not lead to neurotoxicity. For second messenger systems, fluoxetine has shown a potent inhibitory effect on at least one intracellular kinase (Ca 2ϩ /calmodulin-dependent protein kinase) in nonneural cells (Silver et al. 1986 ). Fluoxetine, while a selective 5-HT uptake inhibitor (IC 50 10.2 nmol/L) is not a potent 5-HT releaser unless it is given at very high concentrations (EC 50 ( 3 H-5-HT release): 23.0 mol/L) (Hekmatpanah and Peroutka 1990; Hyde and Bennett 1994) . Cocaine is a highly selective DA and NE uptake inhibitor but is a relatively weak 5-HT releaser in a synaptosomal preparations (EC 50 10.0 mol/L) (Miller et al. 1980; Hyde and Bennett 1994; Kramer and Azmitia 1994) .
Similarly, acute treatment with 5.0 mg/kg DOB was unable to induce a long-term translocation of PKC to cortical membranes. This finding was unexpected when compared to DOB's ability to promote PKC translocation in vitro (Kagaya et al. 1990; Wang and Friedman 1990) . Unfortunately, there is not much evidence of DOB's ability to induce these effects in vivo; therefore, data regarding this response in live animals remain uncertain. However, a single injection of another 5-HT 2A/2C agonist, (Ϯ)-2,5-dimethoxy-4-iodoamphetamine (DOI), produces a rapid desensitization of the 5-HT 2A/2C receptor within minutes of a single low dose (5 mg/kg) (Pranzatelli 1991) . Consequently, the absence of prolonged PKC translocation after a high-affinity agonist, like DOI and DOB, may reflect a consequence of receptor desensitization. This rapid functional loss may be neuroprotective by attenuating the aftermath of prolonged 5-HT 2A/2C receptor activation. Therefore, compounds that are relatively weak 5-HT releasers (FLX and COC)-or rapidly desensitize 5-HT 2A/2C receptors (DOB)-appear not to increase PKC translocation, and this ineffectiveness may explain their low neurotoxic potential.
An increase in extracellular 5-HT appears essential for PKC translocation and for the eventual ablation of fine 5-HT axons by substituted amphetamines. Pretreatment of rats with fluoxetine not only prevents PKC translocation, but also the acute reduction in brain 5-HT levels and the long-term decrease in cortical 5-HT uptake sites after MDMA (this report and Schmidt 1987) . Similarly, depletion of endogenous 5-HT stores prior to administration of neurotoxic doses of pCA or MDMA also blocks their PKC stimulating and neurotoxic effects (Berger et al. 1992a,b; Gu and Azmitia 1993; Kramer et al. 1995) . Consequently, both neurotransmitter release and PKC translocation show a sensitivity to fluoxetine, presumably by interfering with the drug from binding to the 5-HT transporter (SERT) (Berger et al. 1992b; Azmitia et al. 1993) . By inhibiting the 5-HT transporter, FLX blocks MDMA from its primary active site which prevents 5-HT release and/or the entrance of MDMA into the 5-HT nerve terminal (Rudnick and Wall 1992a,b) .
5-HT 2A/2C antagonists like ketanserin are also effective at reducing the neuropathology induced by MDMA . Accordingly, several laboratories have reported that the 5-HT 2A/2C receptor controls many intermediate physiological changes associated with MDMA exposure. Hyperthermia, increases in DA synthesis and release, elevations in intracellular calcium, glycogenolysis in astrocytes, and the potentiation of substituted amphetamine-mediated glucocorticoid release have all been shown to be modulated by activation of this receptor subtype following MDMA (Nash and Brodkin 1991; Schmidt et al. 1991; Malberg et al. 1994; Yau et al. 1994; Novotney and Lowy 1995; Poblete and Azmitia 1995) . Therefore, direct or indirect stimulation of the 5-HT 2A/2C receptor by MDMA (or 5-HT) produces varied metabolic and behavioral changes in exposed animals.
In the present study, ketanserin pretreatment reduced PKC translocation after MDMA administration by 18.7% and by 21.5% after pCA, and each value was significantly different from the stimulant-alone groups (p Յ .05) ( Figure 5) Figure 6 ). Ketanserin pretreatment totally abolished this loss of 5-HT uptake sites in the cerebral cortex (Figure 6) . In contrast, ketanserin only partially blocked PKC translocation, suggesting that kinase activation does not only occur through postsynaptic 5-HT 2A/2C receptor stimulation. However, in the presence of ketanserin, MDMA is still capable of binding to the SERT and stimulating 5-HT release. The partial reversal by ketanserin suggests that 5-HT 2A/2C receptor activation is only one cellular mechanism by which MDMA stimulates PKC translocation and only one factor that contributes to 5-HT toxicity.
One of these other mechanisms may involve stimulation of the 5-HT 3 receptor. Specific 5-HT 3 agonists have been shown to increase phosphoinositide hydrolysis and IP 3 formation in several tissue types (Edwards et al. 1993; Yang et al. 1994 ). Interestingly, 5-HT 3 -mediated phospholipase C (PLC) activation appears to be a calciumdependent process (Edwards et al. 1993 ). This calcium requirement can be readily supplied by the calcium mobilizing properties of MDMA (Park and Azmitia 1991) . Additionally, the inhibitory actions of FLX on MDMAmediated PKC translocation support the possibility that MDMA may also promote PKC translocation within 5-HT nerve terminals. Therefore, besides the participation of 5-HT 2A/2C receptors, PKC translocation after MDMA might occur via alternate mechanisms involving the 5-HT 3 receptor complex and the SERT.
The prolonged activation of PKC after MDMA may have important implications for the development of 5-HT nerve terminal toxicity. Previous studies have shown that sustained PKC translocation-in cerebellar granule cells, in vitro, and in the hippocampus, in vivo-leads to a destabilization of intracellular calcium homeostasis and cell death (Favaron et al. 1988; Onodera et al. 1989) . Of the many cellular mechanisms that are believed to promote the loss of 5-HT nerve terminals after MDMA, an increase in extrasynaptic 5-HT and DA are among the most understood (Berger et al. 1989 (Berger et al. , 1992a Nash 1990 ). Co-administration of a 5-HT 2A/2C agonist, DOI, with MDMA potentates both DA release and 5-HT neurotoxicity (Gudelsky et al. 1994) . Recently, both the DA and 5-HT uptake transporters have been shown to be substrates for PKC-mediated phosphorylation, and this modification significantly decreases monoamine re-uptake (Miller and Hoffman 1994; Huff et al. 1997) . Therefore, PKC activation may potentiate the increase in extracellular DA and 5-HT and contribute to neurotoxicity, by preventing the clearance of monoamines from the synaptic cleft.
In summary, the PKC translocating effects of MDMA and pCA appear to be related to their ability to bind to the 5-HT transporter, release 5-HT from central serotonergic neurons, and to stimulate 5-HT 2A/2C receptors. Additionally, PKC activation may be occurring within the 5-HT nerve terminal in response to MDMA binding to the SERT, coupled with increased calcium influx into the 5-HT terminal bouton. Increases in intracellular calcium can promote PKC translocation in the absence of receptor-stimulated phospholipid hydrolysis. (Melloni et al. 1985) . A fluoxetine-sensitive increase in 45 Ca 2ϩ uptake has been reported to occur in cortical synaptosomes incubated with MDMA concentrations known to release 3 H-5-HT . Fluoxetine was able to totally inhibit MDMA's effect on PKC translocation, presumably by preventing 5-HT release and serotonin receptor stimulation. Our results demonstrate that MDMA increases the density of membrane-bound phorbol ester binding sites when administered acutely in vivo, and that this effect is differentially sensitive to SERT and 5-HT 2A/2C antagonists. We are currently performing similar experiments in vitro, using synaptosomes in different ionic conditions, to fully elucidate the mechanism of this interesting response to substituted amphetamines.
